Biomarkers for chimeric antigen receptor T cell therapy in B cell malignancies can assess therapeutic efficacy and toxicity / 中华检验医学杂志
Chinese Journal of Laboratory Medicine
;
(12): 875-880, 2022.
Artículo
en Chino
| WPRIM
| ID: wpr-958594
ABSTRACT
Chimeric antigen receptor (CAR)-T cell immunotherapy have developed for nearly two decades and achieved great clinical success in the treatment of hematological malignancies. Efficacy monitoring and toxicity management of CAR-T cell immunotherapy are essential steps to ensure safety and improve overall survival in multicenter clinical trials and commercialized treatments. CAR-T cell immunotherapy related biomarkers can be used as an indicator of patient baseline characteristics, tumor biology, and CAR-T cell function. Besides, side effects during treatment can also be assessed by the biomarkers.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Chinese Journal of Laboratory Medicine
Año:
2022
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS